Immunicum to Host Investor Meeting with CEO
Press Release
28 October 2021
Immunicum to Host Investor Meeting with CEO
Immunicum AB (publ; IMMU.ST) today announced that on Monday, 15 November it will host an investor event providing the opportunity to meet with Immunicum’s new CEO Erik Manting in person for the first time. He and other members of the management team will be available to answer questions about the company’s vision, its programs and how it aims to address key challenges in the treatment of cancer.
The Meet-and-Greet event will be informal. As space is limited, attendance will be based on registration on a first-come-first-serve basis.
“Immunicum is committed to executing on its strategy and staying in touch with our shareholders on a proactive basis. After a long period of Covid-19 related restrictions, we look forward to meeting current shareholders, investors and other stakeholders in person, for the first time since I became Immunicum’s CEO,” said Erik Manting, Ph.D., Chief Executive Officer of Immunicum.
The event will be in English; however questions in Swedish are welcome. After the discussion there will be an opportunity to socialize. Light food and drinks will be provided.
Date: Monday, 15 November
Place: Västra Trädgårdsgatan 15, Stockholm (Tändstickspalatset)
Time: 18.00 - 19.00, registration from 17.30
Please register to participate in the Meet-and-Greet event by writing an email to ir@immunicum.com before 10 November.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Investeringsselskabet Artha Optimum A/S - forløb af ordinær generalforsamling24.4.2024 14:55:09 CEST | pressemeddelelse
Selskabsmeddelelse nr. 05, 2024 Hellerup, 24. april 2024 GENERALFORSAMLINGSREFERAT Referat af ordinær generalforsamling i Investeringsselskabet Artha Optimum A/S, CVR. NR. 32 93 78 96 Onsdag, den 24. april 2024, kl. 10:00 Generalforsamlingen afholdtes på selskabets adresse Strandvejen 58, 2900 Hellerup Bestyrelsen udpegede advokat Klaus Lund til dirigent. Dirigenten konstaterede, med generalforsamlingens tilslutning, at generalforsamlingen var lovligt indvarslet og beslutningsdygtig i henhold til dagsordenen. Dagsorden: Bestyrelsens beretning om selskabets virksomhed i det forløbne år.Fremlæggelse af årsrapport til godkendelse.Beslutning om anvendelse af årets resultat.Valg af medlemmer til bestyrelsen.Valg af revisor.VedtægtsændringerEventuelt. 1. Bestyrelsens beretning om selskabets virksomhed i det forløbne år. Bestyrelsen aflagde sin beretning. Generalforsamlingen tog beretningen til efterretning. 2. Fremlæggelse af årsrapport til godkendelse. Årsrapporten for 2023 blev fremlagt og
Novo Nordisk A/S – Reduction of the share capital24.4.2024 14:48:49 CEST | Press release
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 4,500,000. After the reduction of the share capital, the company’s share capital is nominally DKK 446,500,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 339,012,800. The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme, which will continue as previously announced. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our
cBrain takes lead within AI for government24.4.2024 14:48:40 CEST | Press release
Company Announcement no. 07/2024 cBrain takes lead within AI for government Copenhagen, April 24, 2024 cBrain (NASDAQ: CBRAIN) entered 2024 on the back of continued strong organic growth and solid earnings, reporting full-year 2023 results showing a 27% growth year-over-year and EBT (earnings before tax) of 34%. The first months of 2024 show continued business development in line with plans, winning new customers and projects in both Denmark and internationally. Consequently, cBrain maintains its expectations for 2024, forecasting full-year revenue growth of 20-25% and EBT (earnings before tax) of 24-30%. First quarter 2024 has been exciting for cBrain. While executing the growth plan, with a continued focus on F2 Climate Software as an international door opener and developing the F2-for-Partners concept, cBrain has in parallel developed a new F2 standard module for government Artificial Intelligence (AI), called F2 AI Assistant. F2 AI Assistant has been developed in close collaboratio
Vertex Selected to Join Oracle ISV Accelerator for SaaS Initiative24.4.2024 14:00:00 CEST | Press release
Vertex offers customers an optimized business operations and outcomes experience by integrating tax in and around Oracle Fusion Cloud Applications KING OF PRUSSIA, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions and a member of Oracle PartnerNetwork (OPN), today announced that it has been selected to join the Oracle Independent Software Vendor (ISV) Accelerator for SaaS Initiative. With expertise in Oracle Cloud Fusion Cloud Applications integrations, Vertex continues to leverage the power of contract and tax data to optimize customer operations and outcomes. "Building on our longstanding relationship with Oracle, we are thrilled to join the Oracle ISV Accelerator," said Bradd Wildstein, Vice President, Indirect Sales at Vertex, Inc. "Through this partnership, Vertex can now enhance our customers' finance and sales processes by integrating essential tax solutions into Oracle Fusion Application
Reminder: Program for the publication of Yara International ASA first quarter results 202424.4.2024 14:00:00 CEST | Press release
Yara International ASA first quarter 2024 results will be published on Friday, 26 April 2024 at 08:00 CEST. You can follow the presentation of first quarter results at 12:00 CEST. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: https://yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use the link to register for this session: https://registrations.events/direct/Q4I2875784 Registered conference call participants will receive a confirmation with a full list of available international dial-in numbers and a unique passcode. If you do not see the email in a few minutes after completed registration, please check the “junk mail” folder or “spam” folder in your email client. Please join the call 5-10 minutes prior to scheduled start time. Alternatively, it is possible to use the di